Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis

door Vardarli, I., Weidemann, F., Aboukoura, M., Herrmann, K., Binse, I., Görges, R.
Gepubliceerd in BMC Cancer (2020)

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications

door Weidemann, F, Niemann, M, Störk, S, Breunig, F, Beer, M, Sommer, C, Herrmann, S, Ertl, G, Wanner, C
Gepubliceerd in J Intern Med (2013)

Myocardial lipid content in Fabry disease: a combined (1)H-MR spectroscopy and MR imaging study at 3 Tesla

door Petritsch, B., Köstler, H., Weng, A. M., Horn, M., Gassenmaier, T., Kunz, A. S., Weidemann, F., Wanner, C., Bley, T. A., Beer, M.
Gepubliceerd in BMC Cardiovasc Disord (2016)

Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage

door Linthorst, Gabor E., Burlina, Alessandro P., Cecchi, Franco, Cox, Timothy M., Fletcher, Janice M., Feldt-Rasmussen, Ulla, Giugliani, Roberto, Hollak, Carla E. M., Houge, Gunnar, Hughes, Derralynn, Kantola, Iikka, Lachmann, Robin, Lopez, Monica, Ortiz, Alberto, Parini, Rossella, Rivera, Alberto, Rolfs, Arndt, Ramaswami, Uma, Svarstad, Einar, Tondel, Camilla, Tylki-Szymanska, Anna, Vujkovac, Bojan, Waldek, Steven, West, Michael, Weidemann, F., Mehta, Atul
Gepubliceerd in 2012